Limits...
Bone resorption predicts for skeletal complications in metastatic bone disease.

Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE - Br. J. Cancer (2003)

Bottom Line: All skeletal-related events, plus hospital admissions for bone pain and death during the period of observation, were recorded.Data were available for 121 patients over the first 3-month period of monitoring (0-3 months) and 95 patients over the second 3-month period (4-6 months).In a multivariate logistic regression model, Ntx was highly predictive for events/death.

View Article: PubMed Central - PubMed

Affiliation: Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK.

ABSTRACT
Relationships between the rate of bone resorption (measured by urinary N-telopeptide (Ntx) excretion) and a range of skeletal complications have been evaluated in patients with metastatic bone disease. A total of 121 patients had monthly measurements of Ntx during treatment with bisphosphonates. All skeletal-related events, plus hospital admissions for bone pain and death during the period of observation, were recorded. Data were available for 121 patients over the first 3-month period of monitoring (0-3 months) and 95 patients over the second 3-month period (4-6 months). N-telopeptide levels were correlated with the number of skeletal-related events and/or death (r=0.62, P<0.001 for 0-3 months and r=0.46, P<0.001 for 4-6 months, respectively). Patients with baseline Ntx values > or =100 nmol mmol(-1) creatinine (representing clearly accelerated bone resorption) were 19.48 times (95% CI 7.55, 50.22) more likely to experience a skeletal-related event/death during the first 3 months than those with Ntx <100 (P<0.001). In a multivariate logistic regression model, Ntx was highly predictive for events/death. This study is the first to indicate a strong correlation between the rate of bone resorption and the frequency of skeletal complications in metastatic bone disease. N-telopeptide appears useful in the prediction of patients most likely to experience skeletal complications and thus benefit from bisphosphonate treatment.

Show MeSH

Related in: MedlinePlus

Scatter plots of baseline Ntx (log scale) against the number of skeletal complications during (A) 0–3 months and (B) 4–6 months. Median values of Ntx in nmol mmol−1 creatinine were 65.5 (no skeletal complication), 171 (one skeletal complication), 298.5 (two skeletal complications) and 240.5 (three skeletal complications) in (A) and 49.0 (no skeletal complication), 142 (one skeletal complication) and 197.5 (two skeletal complications) in (B).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376859&req=5

fig2: Scatter plots of baseline Ntx (log scale) against the number of skeletal complications during (A) 0–3 months and (B) 4–6 months. Median values of Ntx in nmol mmol−1 creatinine were 65.5 (no skeletal complication), 171 (one skeletal complication), 298.5 (two skeletal complications) and 240.5 (three skeletal complications) in (A) and 49.0 (no skeletal complication), 142 (one skeletal complication) and 197.5 (two skeletal complications) in (B).

Mentions: Figure 2AFigure 2


Bone resorption predicts for skeletal complications in metastatic bone disease.

Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE - Br. J. Cancer (2003)

Scatter plots of baseline Ntx (log scale) against the number of skeletal complications during (A) 0–3 months and (B) 4–6 months. Median values of Ntx in nmol mmol−1 creatinine were 65.5 (no skeletal complication), 171 (one skeletal complication), 298.5 (two skeletal complications) and 240.5 (three skeletal complications) in (A) and 49.0 (no skeletal complication), 142 (one skeletal complication) and 197.5 (two skeletal complications) in (B).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376859&req=5

fig2: Scatter plots of baseline Ntx (log scale) against the number of skeletal complications during (A) 0–3 months and (B) 4–6 months. Median values of Ntx in nmol mmol−1 creatinine were 65.5 (no skeletal complication), 171 (one skeletal complication), 298.5 (two skeletal complications) and 240.5 (three skeletal complications) in (A) and 49.0 (no skeletal complication), 142 (one skeletal complication) and 197.5 (two skeletal complications) in (B).
Mentions: Figure 2AFigure 2

Bottom Line: All skeletal-related events, plus hospital admissions for bone pain and death during the period of observation, were recorded.Data were available for 121 patients over the first 3-month period of monitoring (0-3 months) and 95 patients over the second 3-month period (4-6 months).In a multivariate logistic regression model, Ntx was highly predictive for events/death.

View Article: PubMed Central - PubMed

Affiliation: Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield S10 2SJ, UK.

ABSTRACT
Relationships between the rate of bone resorption (measured by urinary N-telopeptide (Ntx) excretion) and a range of skeletal complications have been evaluated in patients with metastatic bone disease. A total of 121 patients had monthly measurements of Ntx during treatment with bisphosphonates. All skeletal-related events, plus hospital admissions for bone pain and death during the period of observation, were recorded. Data were available for 121 patients over the first 3-month period of monitoring (0-3 months) and 95 patients over the second 3-month period (4-6 months). N-telopeptide levels were correlated with the number of skeletal-related events and/or death (r=0.62, P<0.001 for 0-3 months and r=0.46, P<0.001 for 4-6 months, respectively). Patients with baseline Ntx values > or =100 nmol mmol(-1) creatinine (representing clearly accelerated bone resorption) were 19.48 times (95% CI 7.55, 50.22) more likely to experience a skeletal-related event/death during the first 3 months than those with Ntx <100 (P<0.001). In a multivariate logistic regression model, Ntx was highly predictive for events/death. This study is the first to indicate a strong correlation between the rate of bone resorption and the frequency of skeletal complications in metastatic bone disease. N-telopeptide appears useful in the prediction of patients most likely to experience skeletal complications and thus benefit from bisphosphonate treatment.

Show MeSH
Related in: MedlinePlus